HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen

References

• Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. San Diego, CA: Department of Health and Human Services. Accessed June 2/2/2016.
   Google Scholar
• Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab. 2011;25:501–515.10.1016/j.beem.2010.11.003
   PubMed Web of Science ®Google Scholar
• Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2013;10:26–29.
   Google Scholar
• McComsey GA, O’Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther. 2012;17:347–353.
   PubMed Web of Science ®Google Scholar
• Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25:1289–1298.10.1097/QAD.0b013e328347fa16
   PubMed Web of Science ®Google Scholar
• Readhead AC, Gordon DE, Wang Z, et al. Transmitted antiretroviral drug resistance in New York State, 2006–2008: results from a new surveillance system. PLoS ONE. 2012;7:e40533.10.1371/journal.pone.0040533
   PubMed Web of Science ®Google Scholar
• MacVeigh MS, Kosmetatos MK, McDonald JE, Reeder JL, Parrish DA, Young TP. Prevalence of drug-resistant HIV type 1 at the time of initiation of antiretroviral therapy in Portland, Oregon. AIDS Res Hum Retroviruses. 2013;29:337–342.
   PubMed Web of Science ®Google Scholar
• Negredo E, Miró Òscar, Rodríguez‐Santiago B, et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse‐transcriptase inhibitor–sparing strategy: results from the multicenter study with nevirapine and kaletra (multineka). Clin Infect Dis. 2009;49:892–900.10.1086/599189
   PubMed Web of Science ®Google Scholar
• Valantin MA, Lanoy E, Bentata M, et al. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med. 2008;9:625–635.10.1111/hiv.2008.9.issue-8
   PubMed Web of Science ®Google Scholar
• Casado JL. Renal and bone toxicity with the use of tenofovir: understanding at the end. AIDS Rev. 2016;18:59–68.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61.
   PubMed Web of Science ®Google Scholar
• Marcus JL, Neugebauer RS, Leyden WA, et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals. J Acquir Immune Defic Syndr. 2016;71:413–419.10.1097/QAI.0000000000000881
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–2106.10.1056/NEJMoa074609
   PubMed Web of Science ®Google Scholar
• Reynes J, Lawal A, Pulido F, et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. HIV Clin Trials. 2011;12:255–267.10.1310/hct1205-255
   PubMed Web of Science ®Google Scholar
• Kozal MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13:119–130.10.1310/hct1303-119
   PubMed Web of Science ®Google Scholar
• Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25:2113–2122.10.1097/QAD.0b013e32834bbaa9
   PubMed Web of Science ®Google Scholar
• Boyd MA, Kumarasamy N, Moore CL, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013;381:2091–2099.
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–265.
   PubMed Web of Science ®Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–1951.10.1016/S0140-6736(14)61170-3
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23:1109–1118.10.1097/QAD.0b013e32832b4377
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–831.10.1097/QAD.0b013e32835192ae
   PubMed Web of Science ®Google Scholar
• Bernardino JI, Mocroft A, Mallon PW, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015;2:e464–e473.10.1016/S2352-3018(15)00181-2
   PubMed Web of Science ®Google Scholar
• Karris MY, Jain S, Bowman VQ, et al. Nucleoside-sparing regimens with raltegravir and a boosted protease inhibitor: an unsettled issue. J Acquir Immune Defic Syndr. 2016;72:e48–50.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–1126.10.1093/cid/cir627
   PubMed Web of Science ®Google Scholar
• Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17:118–123.
   PubMedGoogle Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.10.1146/annurev-med-042909-093756
   PubMed Web of Science ®Google Scholar
• Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the national institute of allergy and infectious diseases, division of AIDS. Cytometry. 1993;14:702–715.10.1002/(ISSN)1097-0320
   PubMedGoogle Scholar
• Andrade A, Guedj J, Rosenkranz SL, et al. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS. 2015;29:2419–2426.10.1097/QAD.0000000000000843
   PubMed Web of Science ®Google Scholar
• Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007;21:2315–2321.10.1097/QAD.0b013e3282f12377
   PubMed Web of Science ®Google Scholar
• Andrade A, Rosenkranz SL, Cillo AR, et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013;208:884–891.10.1093/infdis/jit272
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, Ribaudo H, et al. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. AIDS. 2011;25:2269–2278.10.1097/QAD.0b013e32834d0c20
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.10.1056/NEJMoa1105243
   PubMed Web of Science ®Google Scholar
• Mujugira A, Celum C, Coombs RW, et al. HIV transmission risk persists during the first 6 months of antiretroviral therapy. J Acquir Immune Defic Syndr. 2016;72:579–584.
   Web of Science ®Google Scholar
• Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother. 2010;54:1047–1054.10.1128/AAC.01537-09
   PubMed Web of Science ®Google Scholar
• Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449–455.10.1097/QAI.0b013e3182965d45
   PubMed Web of Science ®Google Scholar
• Funderburg NT, Andrade A, Chan ES, et al. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naive patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One. 2013;8:e83514.
   PubMed Web of Science ®Google Scholar
• Lees O, Ramzaoui S, Gilbert D, et al. The impaired in vitro production of interleukin-2 in HIV infection is negatively correlated to the number of circulating CD4+ DR+ T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation. Clin Immunol Immunopathol. 1993;67:185–191.10.1006/clin.1993.1063
   PubMedGoogle Scholar
• Spina C, Prince H, Richman D. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest. 1997;99:1774–1785.10.1172/JCI119342
   PubMed Web of Science ®Google Scholar
• Tang S, Patterson B, Levy JA. Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol. 1995;69:5659–5665.
   PubMed Web of Science ®Google Scholar
• Zack J. The role of the cell cycle in HIV-1 infection. Adv Exp Med Biol. 1995;374:27–31.10.1007/978-1-4615-1995-9
   PubMedGoogle Scholar
• Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1:a007096.
   PubMed Web of Science ®Google Scholar
• Battegay M, Elzi L. Does HIV antiretroviral therapy still need its backbone? Lancet. 2014;384:1908–1910.10.1016/S0140-6736(14)61226-5
   PubMed Web of Science ®Google Scholar